IMUX
Immunic, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Immunic has 7 disclosed suppliers and 0 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceOn March 31, 2021, Immunic AG and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million.
IMUX 10-Kaccession 0001280776-26-000005
SentenceFor instance, in November 2018, Immunic AG and Daiichi Sankyo entered into a license and option agreement that grants us an exclusive global option to license IMU-856 and related molecules.
IMUX 10-Kaccession 0001280776-26-000005
SentenceWe also conduct preclinical work in our laboratory in Martinsried, Germany and in Halle/Saale, Germany and through a collaboration with the Fraunhofer Institute.
IMUX 10-Kaccession 0001280776-26-000005
SentenceThe increase was primarily attributable to (i) $4.8 million of grant income from the German Federal Ministry of Finance, of which $1 million was recognized in the first quarter 2025 and $3.8 million was recognized in the fourth quarter 2025, (ii) a $1.7 million expense related to the portion of deal costs from the January 2024 Financing related to the tranche rights that were established at the time of the deal closing in 2024 and (iii) a $0.3 million increase across numerous categories.
IMUX 10-Kaccession 0001280776-26-000005
SentenceOther Commitments and Obligations See Note 2 - Collaboration Arrangements of the Notes to the Financial Statements regarding the Company's obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856 and the Ludwig-Maximilians-University Agreements where the Ludwig-Maximilians-University is entitled to receive future development, regulatory and sales milestone payments related to these molecules.
IMUX 10-Kaccession 0001280776-26-000005
SentenceOn January 5, 2026, we were notified by the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that our application to transfer the listing of our Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market had been approved (the "Approval").
IMUX 10-Kaccession 0001280776-26-000005
SentenceOn September 9, 2025, we announced that we received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for patent application 18/529,946, entitled "Treatment of multiple sclerosis comprising DHODH inhibitors."
IMUX 10-Kaccession 0001280776-26-000005
Largest filed tie
—
Immunic, Inc.
7.53
—
—
Expected move
Inputsspot 7.51exp Nov 20ATM strike 7.5ATM straddle 2.47IV 174%